Guiding neuro-oncology therapies from early detection of response to approval. Partner with a small, flexible CRO who cares about your research as much as you do.
TD2 provides innovative services for improved and accelerated development of therapies for glioblastoma and neuro-oncology. Our team has deep experience and understanding of GBM PDX models for preclinical development. This combined with regulatory strategy expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent and the rapid identification of clinically significant endpoints.
Brands: Glioblastoma PDX Models
Regulatory Strategy & Support
Comprehensive Clinical Trial Management